ArticleMicrosystems & nanoengineering2026
An automated, digital immunoassay on a microfluidic cartridge for on-demand cytokine profiling.
Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Patients with critical illness often exhibit profound biological heterogeneity, complicating the identification of effective interventions. Resolving distinct molecular profiles to enable timely treatment decisions remains challenging, as integrating biomarker-guided care into routine monitoring is often hindered by fragmented, batch-based workflows. These manual operations decouple molecular data from the acute clinical timeline and are a barrier to reliable, real-time, near to patient, multi-center implementation. To address this gap, we developed an integrated microfluidic digital immunoassay system that achieves high analytical fidelity through a fully automated, simple workflow. The system utilizes a monolithic disposable cartridge to automate bead-based analyte capture, oil-phase partitioning, and signal amplification, eliminating the manual handling and emulsion steps that typically compromise digital assay robustness. The platform enables protein measurement within 45 minutes, achieving sub-picogram limit of detection ( < 0.13 pg/mL), a dynamic range spanning three orders of magnitude, and strong analytical reproducibility. We demonstrate the clinical utility of the system by profiling a validated panel of inflammatory biomarkers in plasma from critically ill pediatric patients, using low sample volumes. Results show strong agreement with gold-standard multiplex assays (R
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.